Does Insurance Cover Osphena? What 12 Real Plan Documents Say in 2026

The HRT Index Editorial TeamIndependent women's health research

Published:August 26, 2026Last reviewed:August 26, 2026

Editorial research — not medically reviewed by a clinician. Why this label

Last updated: August 26, 2026 · Last verified: August 26, 2026 · By The HRT Index Editorial Team. Educational research, not medical advice, and not reviewed by a clinician. See our medical review policy. Full disclosure.

Coverage is one part of the decision

Compare your coverage situation, medication route, state, and safety flags before paying cash or appealing a prescription denial.

Find My HRT Path

Sometimes. Osphena is covered by some commercial, Medicare Part D, and Medicaid plans, usually with prior authorization, a quantity limit, step therapy, or a higher tier. Some commercial and Medicaid policies cover vaginal dryness while excluding dyspareunia. Current manufacturer routes run from $35 for 30 tablets with eligible commercial insurance to $190 for 90 tablets cash.

That diagnosis split is the whole reason this page exists. It is written into UnitedHealthcare's current commercial policy, Kaiser Permanente Northwest's criteria, and an Iowa Medicaid prior-authorization form. Medicare Part D is different: CMS has clarified that FDA-labeled treatment for moderate-to-severe dyspareunia due to menopause is not automatically excluded as a sexual-dysfunction drug.

We read 12 real plan documents to figure out what changes the answer. Here is where you probably stand.

Your status	What it looks like	What actually fixes it
1. Listed, but prior authorization or step therapy applies	The pharmacy says “needs PA,” “needs approval,” or “step therapy required”	Your prescriber submits the plan's required documentation, prior-treatment history, or exception reason.
2. Covered for one diagnosis but not the other	The same drug is approvable for vaginal dryness but denied for dyspareunia	Ask which diagnosis and benefit rule were reviewed. Your prescriber should submit the full, accurate clinical picture — never a diagnosis that is not true.
3. Not listed or specifically excluded	The claim says “nonformulary,” “not covered,” or “excluded”	Ask for the plan's nonformulary or coverage-exception process. This is not the same request as an ordinary prior authorization.
4. Covered, but still painfully expensive	Osphena is on a non-preferred tier, subject to a deductible, or limited to a certain quantity	Get a test claim, ask whether a tiering exception exists, and compare the insured price with the current manufacturer routes.

Best for: women who already have an Osphena prescription, a scary pharmacy quote, a restriction, or a written denial and want to know what changes the outcome.

Not for you if: you are still deciding which treatment is appropriate. Local low-dose vaginal estrogen has the most robust evidence base among hormonal GSM treatments, but treatment selection should be shared with a clinician — not dictated by an insurer's sequence. Start with our vaginal estrogen guide instead.

If you have Medicare, Medicaid, TRICARE, or another government plan, read this first

The Osphena commercial savings offers are not available to you. The January 2026 savings-card terms exclude people enrolled in Medicare, Medicaid, TRICARE, or another federal or state healthcare plan. That is why the advertised $35 commercial-insurance price does not apply.

There is still a cash route. It has a real Medicare trade-off, and we walk through it below. No links or offers in this box on purpose.

The right online HRT provider isn't the same for every woman — it depends on your symptoms, your age and whether you have a uterus, your medication route preference (patch, pill, gel, or vaginal estrogen), your risk history, your insurance or cash-pay situation, and your state. Some situations belong with an in-person clinician first. Because a general answer can't resolve those for you, use The HRT Index's Find My HRT Path tool to match your situation to the right provider — and to flag when online care isn't the right starting point — before your first consult.

Get my personalized HRT starting-point plan →

The HRT Index is the independent decision resource for online menopause and HRT care — comparing telehealth providers on clinical legitimacy, care quality, medication fit, price transparency, and access, with every claim verified and dated, so women can choose the path that fits their situation before their first consult.

One thing before you read further: the cheapest answer on this page is usually a generic vaginal cream that pays us nothing. The next route is the manufacturer's own phone line, which also pays us nothing. We have two affiliate partners on this page, and neither one is the right answer for most women who land here. We'll tell you when they are, and we'll tell you when they aren't.

Does insurance cover Osphena?

Some insurance plans cover Osphena, but the word “covered” hides five separate decisions. Across the 12 documents we verified, Osphena appears as a preferred drug, a prior-authorization drug, a diagnosis-sensitive drug, a Tier 3 drug with a quantity limit, and an excluded drug. Your exact plan document and live pharmacy claim decide which version is yours.

That's the honest answer. Now here's the useful part.

Most articles stop at “it depends on your plan.” That's true and useless. What you actually need to know is what it depends on, because each thing has a different fix.

There are five separate switches:

Is Osphena on your drug list at all? It may be listed, nonformulary, or specifically excluded.
What tier is it on? A covered drug on a non-preferred tier can still hurt.
Are there extra rules? Prior authorization, step therapy, a quantity limit, or reauthorization.
Does the benefit apply a category exclusion? Some commercial and Medicaid rules separate dyspareunia from vaginal dryness.
Where are you in your plan year? A covered drug may still cost hundreds before you meet the deductible.

Five switches. One question. That's why “does insurance cover Osphena” does not have a clean yes-or-no answer — and why a page that gives you one is guessing.

What a public plan document cannot tell you. We read a lot of PDFs for this page. They cannot prove that you are enrolled in that exact plan version, that your employer adopted the same formulary, that the pharmacy benefit manager is applying it today, that your diagnosis and quantity satisfy the rule, or what you will pay at your pharmacy. Public documents show the shape of the rule. Your member-specific formulary, live test claim, and written denial control the outcome.

We are also not going to publish a national “percentage of plans that cover Osphena.” We did not find a credible national enrollment-weighted coverage dataset. A percentage without that denominator would be theater.

Why can the diagnosis on an Osphena request change coverage?

Some commercial plans and Medicaid programs treat dyspareunia as a sexual-dysfunction indication while treating vaginal dryness as a separate FDA-approved indication. That can produce opposite coverage decisions for the same 60 mg tablet. Medicare Part D is different: CMS clarified that FDA-labeled treatment of menopausal dyspareunia is not automatically excluded, although each plan can still use its formulary and utilization rules.

This is the single most important thing on this page. Let's slow down.

The law has an “unless” — and Medicare has a clarification

Federal law contains an exclusion category for drugs used to treat sexual or erectile dysfunction. Both Social Security Act §1860D-2 for Part D and §1927(d)(2)(K) for Medicaid include an exception when the drug is used for another FDA-approved condition.

That statutory wording created confusion around menopausal dyspareunia. In May 2018, CMS issued a Part D clarification stating that drugs used consistently with FDA labeling to treat moderate-to-severe dyspareunia due to menopause are not excluded from Part D on that basis. The CMS memo is preserved in the agency's May 7–11, 2018 HPMS archive, and the clarification is described in a peer-reviewed Journal of Women's Health article.

So the correct rule is not “Medicare cannot cover Osphena for painful sex.” A Part D plan can cover it for either FDA-approved indication, subject to the plan's formulary, prior-authorization criteria, quantity limits, and member-specific benefit.

Medicaid and commercial plans can still produce a diagnosis split. Some do, in writing.

One drug, two FDA-approved indications

The current FDA label lists two uses for Osphena:

February 26, 2013: FDA initially approved Osphena for moderate-to-severe dyspareunia, a symptom of vulvar and vaginal atrophy due to menopause.
January 2019: FDA added moderate-to-severe vaginal dryness, also due to menopause.

One drug. Two approved conditions. Some benefit designs classify them differently.

Three plan documents that put the split in writing

UnitedHealthcare commercial plans — Program 2026 P 1277-8, effective June 1, 2026, has two tracks. Benefit designs that cover sexual-dysfunction medications may approve either FDA-approved diagnosis. Benefit designs that exclude that category list vaginal dryness as the approvable route. Authorization is 12 months.

Kaiser Permanente Northwest — its coverage criteria, revised June 8, 2023, say dyspareunia is covered only for members whose prescription benefit covers medications used to treat sexual dysfunction. The same document also allows coverage for symptoms of genitourinary syndrome of menopause, subject to its treatment criteria.

Iowa Medicaid — Form 470-5601 says requests based on moderate-to-severe dyspareunia will be denied and payment is considered for moderate-to-severe vaginal dryness after an adequate trial of a preferred vaginal estrogen, unless medically contraindicated.

What to do with this — and what not to do

Let's be very clear, because this matters more than a copay.

This is not a script for saying something untrue. It is a reason to make sure the request contains the full, accurate clinical picture. If moderate-to-severe vaginal dryness is genuinely part of your symptoms and is documented, your prescriber should not reduce the entire visit to one shorthand term. If vaginal dryness is not part of your picture, that route is closed.

Ask two clean questions:

“Which FDA-approved diagnosis did the plan review?”
“Does my benefit apply a sexual-dysfunction exclusion to this request?”

And if you have been carrying around the feeling that the plan thinks your problem is frivolous? It does not know you. It has a category code. That's all this is.

Not sure what the plan reviewed? Record the exact submitted diagnosis and denial wording in the Osphena coverage worksheet. One accurate line can change everything downstream.

What do 12 real plan documents actually require?

The 12 documents do not point to one national rule. They show five different outcomes: preferred coverage, prior authorization without a prerequisite drug, prior authorization after one or more trials, Tier 3 coverage with a quantity limit, and outright formulary exclusion. Every cell below comes from a named document that was open and current when checked in August 2026.

This is the table we could not find anywhere, so we built it.

Plan document	Document date	What the document says	Diagnosis treatment	Required first step	Approval or listing
UnitedHealthcare commercial — Program 2026 P 1277-8	Effective June 1, 2026	Prior authorization	Either diagnosis if the benefit covers sexual-dysfunction drugs; vaginal dryness only if it excludes them	No prerequisite product stated in this policy	12 months
CVS Caremark — Osphena criteria 961-A	UDR 01-2024	Initial prior authorization	Either FDA-approved diagnosis	No prerequisite product stated in this document	12 months
Kaiser Permanente Northwest	Revised June 8, 2023	Criteria-based coverage; no quantity limit	GSM symptoms, or dyspareunia when the benefit covers sexual-dysfunction drugs	Estradiol vaginal cream and vaginal tablets, unless physically or mentally unable to apply or insert vaginal estrogen	Duration not stated
Iowa Medicaid — Form 470-5601	Form revision January 2020; still posted on the current PA site when checked	Prior authorization	Vaginal dryness only; dyspareunia requests denied under the form	Adequate trial and failure of one preferred vaginal estrogen, unless medically contraindicated	3 months initially
Centene / Ambetter — CP.PMN.168	Last reviewed November 2025	Medical-necessity criteria for commercial, marketplace, and Medicaid lines	Either FDA-approved diagnosis	Two vaginal lubricants or moisturizers and at least four weeks of one vaginal estrogen, unless the written exceptions apply; Illinois marketplace step requirements do not apply from Jan. 1, 2026 under the policy note	12 months or requested duration if shorter for commercial
Neighborhood Health Plan of Rhode Island Medicaid	Reviewed March 2026	Step-therapy claim logic	FDA-labeled use	Inadequate response or intolerance to formulary estradiol/Yuvafem tablet or estradiol cream	12 months
Cigna Performance 4-Tier PDL	Coverage starting July 1, 2026	Listed Tier 3 + QL	Formulary listing does not split diagnoses	Quantity limit; member plan controls the amount	Formulary listing
Cigna Value 3-Tier PDL	Coverage starting July 1, 2026	Listed Tier 3 + QL	Formulary listing does not split diagnoses	Quantity limit; member plan controls the amount	Formulary listing
Express Scripts 2026 National Preferred Formulary	2026 formulary	Osphena appears in the exclusion table	Both indications affected by the drug-level exclusion	Preferred alternatives named: estradiol cream, estradiol vaginal inserts, Premarin Cream	Coverage review may be requested for clinical need
Express Scripts 2026 National Preferred Flex exclusions	Edition dated July 1, 2026	Osphena is excluded	Both indications affected by the drug-level exclusion	Same named preferred alternatives	Coverage review may be requested for clinical need
Mass General Brigham Health Plan Part D employer-group criteria	Effective August 1, 2026; updated July 2	Prior authorization	All FDA-approved indications	Explicitly says no prerequisite Part D drug is required	Plan year
UMWA Health and Retirement Funds Standard Formulary	Effective July 1, 2026	Osphena 60 mg listed Preferred	Formulary listing does not split diagnoses	No Osphena-specific restriction shown on the listing	Preferred formulary status

Four things this table proves that no single plan page will tell you

1. “You have to fail the cream first” is not a universal rule. It is written into Kaiser Northwest, Iowa Medicaid, Centene, and Neighborhood Health Plan of Rhode Island. It does not appear in the published Osphena criteria we reviewed from CVS Caremark or UnitedHealthcare, and Mass General Brigham's Part D criteria explicitly say no prerequisite Part D drug is required.

2. A paid claim can matter more than a sentence in your chart. Neighborhood Health Plan of Rhode Island's automated logic looks for a paid claim for a formulary vaginal-estrogen product or Osphena in the previous 365 days. “I tried it years ago” may be clinically true and still fail the computer check.

3. “Excluded” and “Tier 3” are completely different problems. The Express Scripts lists exclude Osphena and direct the prescriber toward a coverage review. The Cigna lists place it on Tier 3 with a quantity limit. One is an access problem. The other may be a quantity-and-cost problem. Filing the wrong request wastes time.

4. Medicare Part D coverage is not legally limited to vaginal dryness. The Mass General Brigham Part D criteria accept all FDA-approved indications, exactly as the CMS clarification predicts. That is why a commercial diagnosis split should never be copied into a Medicare answer without checking the Part D rule.

Two footnotes we owe you. Express Scripts says not every plan adopts its national list, and its exclusions do not establish your Medicare coverage. Cigna says its public list may not match every member's benefit. Your card, portal, and test claim still win.

What do PA, ST, QL, “not listed,” and “excluded” actually mean?

These codes describe different obstacles with different owners. PA means the prescriber's office must submit information before the plan decides. ST means the plan wants a prior treatment or a documented exception. QL caps the covered quantity. “Not listed” or “excluded” usually moves you into a nonformulary or coverage-review process. None of those phrases tells you the next step by itself.

Print this one out.

Code or status	What it actually means	Who has to act	The exact question to ask
PA — prior authorization	The plan wants information before it decides. Approval is not guaranteed merely because paperwork was filed.	Prescriber's office	“Which PA form and which criteria apply to my plan and submitted diagnosis?”
ST — step therapy	The plan wants proof of one or more prior products, unless an exception applies.	Prescriber; you can obtain the rule	“What exact product, minimum duration, and exception standard apply?”
QL — quantity limit	The plan caps tablets or days' supply per fill.	Pharmacy and prescriber	“What quantity is covered, and does the claim match one 60 mg tablet daily?”
Non-preferred / Tier 3	The drug is listed but may carry higher coinsurance or copay. Tier numbers have no universal dollar meaning.	Member services	“What is my cost before and after the deductible, and is a tiering exception available?”
Not listed / nonformulary	The drug is absent from the member's current list.	Member and prescriber	“What is the nonformulary or coverage-exception process for my plan?”
Excluded	The contract excludes the drug or a category. Some exclusions allow clinical review; others do not.	Member services, then appeals	“Is this drug-specific or category-wide? Send the exclusion and review rights in writing.”
Reauthorization	Continued coverage depends on documented response or renewed review.	Prescriber	“When does mine expire, and what response documentation is required?”

Here's the thing worth internalizing: a restriction is an administrative condition, not a medical opinion. Your plan is telling you what it wants on file. That sentence is about the benefit. It is not a verdict on your symptoms.

How do I check whether my own plan covers Osphena?

Search the current plan-year formulary for both “Osphena” and “ospemifene,” then get a live test claim for the prescribed quantity. Record the tier, PA/ST/QL codes, diagnosis reviewed, deductible effect, 30- and 90-day cost, and exception process. Ask for the rule in writing; a representative's summary is weaker evidence than the formulary entry, criteria document, or denial letter.

The seven-step check

Read the exact plan name from your card or portal — not just “Blue Cross,” but the plan, employer or marketplace status, and whether it is commercial, Medicare, or Medicaid.
Open the current plan-year drug list. Do not rely on a search result from two years ago. Formularies can change during the year.
Search both names: Osphena and ospemifene.
Write down the tier and every code beside the drug.
Open the legend and decode PA, ST, QL, nonformulary, and any plan-specific symbol.
Ask an in-network pharmacy to run a test claim for the prescribed quantity. You do not have to pick it up. This produces your number, not an internet average.
Ask member services for the written rule and exception process. Save the portal message, formulary page, or denial.

What to say when you call

Use the prescription-benefit number on your card, not the general medical line.

“I'm checking my prescription benefit for Osphena 60 mg, also called ospemifene. Is it on my current drug list? What tier? Does it require prior authorization, step therapy, or have a quantity limit? Which diagnosis was reviewed? Does my plan apply a sexual-dysfunction exclusion to this request? What 30-day and 90-day quantities are covered? Is mail order required or cheaper? Does my deductible affect the quote? What review or exception process applies if it is not covered? Please send the answer and the controlling document to me in writing or through the portal.”

That last sentence is the one people forget, and it is the one that matters in an appeal.

The Osphena coverage worksheet

This worksheet turns the coverage question into a record a plan can actually use. It captures the exact plan, diagnosis reviewed, benefit manager, restriction codes, prior-product history, exception facts, and accumulator status. Fill it from documents you already have; do not guess, and do not change a diagnosis or treatment history to fit a policy.

Fill this in before the next call or appointment. It is the whole page in eight lines. No download, no email, nothing to sign up for.

What to record	Where to get it	Why it changes the outcome
Exact plan name and plan type	Insurance card and portal	Determines which formulary, law, and appeal process apply
Submitted diagnosis	Denial, pharmacy, or prescriber's office	Some commercial and Medicaid rules split the two FDA-approved indications
Whether vaginal dryness and dyspareunia are both accurately documented	Prescriber	The request should reflect the complete, true clinical record
Pharmacy benefit manager	Card or member services	Tells you which formulary and criteria documents to search
Tier and every code beside Osphena	Current drug list	Each code points to a different fix
Prior product, dose, dates, fill history, and what happened	Your records and pharmacy history	Some plans require documentation; one policy checks paid claims in the previous 365 days
Any true inability, contraindication, intolerance, or adverse effect	You and your clinician	Kaiser, Centene, Iowa, and other policies contain written exception routes
Copay accumulator or maximizer status	Ask member services by name	Determines whether manufacturer-assistance dollars count toward your deductible or out-of-pocket maximum

Use only facts that are true and documented in your history. This worksheet organizes the record. It does not create one.

Does Medicare cover Osphena?

A Medicare Part D plan — including drug coverage bundled with Medicare Advantage — can cover Osphena for either FDA-approved indication. CMS clarified that FDA-labeled treatment of moderate-to-severe dyspareunia due to menopause is not automatically excluded as sexual-dysfunction treatment. The remaining answer is plan-specific: formulary status, prior authorization, quantity limits, pharmacy network, deductible, and the 2026 Part D benefit all affect access and cost.

The federal rule matters because the original diagnosis split from some commercial and Medicaid documents does not transfer automatically to Part D.

One current Part D document proves the point

Mass General Brigham Health Plan's 2026 employer-group Part D criteria list Osphena for all FDA-approved indications, require prior authorization, require no prerequisite Part D drug, and approve it for the plan year.

That does not prove your plan covers it. It proves the legal answer is not “Medicare can only cover vaginal dryness.”

The manufacturer names three Part D plan brands — treat that as a lead, not proof

The January 2026 manufacturer card says Osphena is a preferred Part D brand with AARP/UnitedHealthcare, Wellcare, and Humana. That is a manufacturer statement, not a member-specific benefit verification. Formularies vary by contract, county, pharmacy, and year.

During Medicare open enrollment, enter Osphena into Medicare Plan Compare and check the actual plan's pharmacy network and restrictions. A brand name on a marketing card is a place to look, not a promise.

If you pay cash on Medicare, the money does not count toward your Part D cap

The same manufacturer card has separate terms for Part D members who pay cash outside the benefit. Those terms say the cash payment cannot be submitted for Part D reimbursement and does not count toward the True Out-of-Pocket threshold.

For 2026, Medicare says the annual out-of-pocket threshold for covered Part D drugs is $2,100. Once that threshold is reached, the member pays no out-of-pocket amount for covered Part D drugs for the rest of the calendar year.

That creates a real trade-off:

If Osphena is your only expensive medication, the manufacturer's $190-for-90-tablets cash route may be less painful than a high deductible or coinsurance.
If you take several expensive covered Part D drugs and expect to reach the $2,100 threshold, keeping covered claims inside Part D may be better because those dollars move you toward the cap.

Nobody can choose that math for you from a national article. But now you know the trade.

What to ask a Part D plan

“Is Osphena 60 mg on my 2026 formulary for its FDA-approved indication? What tier, quantity limit, and prior-authorization criteria apply? What is my cost at a preferred retail pharmacy and preferred mail-order pharmacy? If it is not covered, what coverage determination or formulary-exception process applies?”

A Part D coverage determination can be requested by you, an authorized representative, or the prescriber. A formulary exception needs the prescriber's supporting statement. Use the deadline in your notice.

Does Medicaid cover Osphena?

Some state Medicaid programs cover Osphena with prior authorization, and some restrict the dyspareunia indication. Federal Medicaid law permits restrictions on drugs used for sexual dysfunction, with an exception for another FDA-approved condition, but each state and managed-care plan writes its own preferred-drug list and form.

Three current examples show how wide the spread is:

Iowa Medicaid denies the dyspareunia indication under its posted form and considers vaginal dryness after a preferred vaginal-estrogen trial, with a three-month initial authorization.
Neighborhood Health Plan of Rhode Island Medicaid requires inadequate response or intolerance to a formulary vaginal-estrogen tablet or cream, and its automated logic can look for a paid claim in the prior 365 days.
Centene's multi-line policy requires two vaginal lubricants or moisturizers plus at least four weeks of one vaginal estrogen, unless the written exception applies. The policy itself states that those step requirements do not apply to Illinois marketplace requests from January 1, 2026.

Do not search “Does Medicaid cover Osphena?” and stop at a national answer. Search your state, your managed-care plan, “Osphena,” and “prior authorization.”

Do I have to try vaginal estrogen or lubricants first?

At some plans, yes. Kaiser Northwest requires documented failure of estradiol vaginal cream and vaginal tablets unless the patient cannot apply or insert vaginal estrogen. Iowa Medicaid requires one preferred vaginal estrogen. Centene requires two lubricants or moisturizers plus a four-week vaginal-estrogen trial. CVS Caremark, UnitedHealthcare, and the Mass General Brigham Part D criteria we reviewed do not state a prerequisite product.

There is no universal “fail the cream first” rule. There are plan documents.

The door most women never hear about

Kaiser Permanente Northwest will allow Osphena without the vaginal-estrogen trials when the patient is physically or mentally unable to apply or insert vaginal estrogen.

That can matter for a woman with a genuine mobility, dexterity, cognitive, trauma-related, or other barrier that makes application or insertion impossible. The policy does not turn every difficult experience into an automatic approval. It creates a written pathway when the barrier is real and documented.

Centene and Iowa also provide routes when required products are medically contraindicated or cause qualifying adverse effects. Those are not favors. They are criteria.

What actually counts as a documented trial

Plans commonly look for:

product name;
dose and route;
start and stop dates or fill dates;
whether the product was actually obtained;
what happened — inadequate response, intolerance, adverse effect, or contraindication.

“I didn't like it” is hard for an authorization reviewer to use. “Used [product] at [dose] from [date] to [date]; symptoms did not improve” gives the office something concrete to submit.

Two cautions. First, some plans check paid claims, so a sample, cash purchase, or trial from years ago may not appear automatically. Second, nobody should start or stop a medication just to satisfy paperwork. The clinical decision comes first. The coverage record follows it.

Ready to put the history into the format a plan can read? Return to the Osphena coverage worksheet.

What cheaper alternatives do plans usually cover first?

The alternatives named most often in the documents we reviewed are generic estradiol vaginal cream, estradiol vaginal tablets or inserts, and Premarin Vaginal Cream. The Express Scripts exclusion lists name them directly. Kaiser and Iowa build vaginal estrogen into their criteria. The 2025 AUA/SUFU/AUGS guideline says local low-dose vaginal estrogen has the most robust evidence base among hormonal GSM options.

Here is the part where we may talk you out of Osphena.

A GoodRx price snapshot checked August 26, 2026 listed one 42.5-gram tube of generic estradiol 0.01% vaginal cream at $35.09 with a coupon. Local pharmacy prices, insurance prices, dose, and how long the tube lasts vary. That is still a radically different starting number from a high retail quote for Osphena.

If local vaginal estrogen is clinically appropriate for you and acceptable to use, it may be the cheaper, easier route. Go to our vaginal estrogen guide. We make no money from that recommendation.

But.

Osphena exists for women who want or need an oral option after a clinician reviews the label, their history, and the alternatives. It may be considered when a vaginal route is not workable, prior options were not tolerated or did not help, or patient preference points elsewhere after shared decision-making.

The 2025 AUA/SUFU/AUGS Genitourinary Syndrome of Menopause Guideline is explicit that treatment should not be reduced to a mandatory clinical ladder. Insurers may impose one. Good medicine is still individualized.

How much does Osphena cost with insurance — and without it?

The manufacturer's lowest published routes are $30 per month on a 90-day commercial-insurance mail-order fill and about $63.33 per month on its 90-day cash program. The retail commercial savings card lists $45 for 30 tablets. A manufacturer-funded GoodRx route lists $85 for 30 or $205 for 90. Your pharmacy's live claim remains the only number that is actually yours.

Every manufacturer figure below was verified on the live Osphena savings page and the January 2026 savings card on August 26, 2026.

How you are buying it	30 tablets	90 tablets	Approximate monthly cost	Who the published route is for
Osphena At Home — commercial insurance	$35	$90	$30–$35	Eligible commercial-insurance patients, subject to terms
Retail Osphena savings card	$45	Not published	$45	Eligible commercial-insurance patients, subject to terms
Osphena At Home — cash	Not published	$190	$63.33	People without prescription coverage or whose insurance does not cover Osphena, subject to terms
Manufacturer-funded GoodRx offer	$85	$205	$68.33–$85	Cash route; GoodRx is not insurance

Four things the headline price does not tell you

1. The manufacturer's two commercial prices are different. Mail order lists $35 for 30 tablets or $90 for 90. Retail lists $45 for 30. If both routes work for you, the 90-day mail-order price works out to $360 a year — $60 less than twelve $35 fills and $180 less than twelve $45 retail fills.

2. The cash mail-order offer is published only as a 90-day price. A one-month cash request may not receive the $190-for-90-tablets program price. Ask exactly what quantity the program requires before the prescription is sent.

3. “As little as” is not a promise. The card says the $35 patient-expense estimate is based on an average prescription filled by patients with prescription coverage. Eligibility, plan design, pharmacy processing, and program terms still control.

4. A covered drug can cost more than the cash route. If your plan applies a deductible or high coinsurance, compare the live insured claim with $190 for 90 tablets. Do not assume “insurance” is automatically the cheaper column.

Get your real number instead of an estimate: ask the pharmacy to run the claim for the prescribed quantity and tell you the exact patient cost without dispensing it. Then compare it with the current manufacturer page on the same day.

Manufacturer contacts published with the program:

Osphena At Home: (844) 716-HOME (4663)
Retail savings-card questions: (347) 657-9766
General product questions: 1-855-677-4362

Can I use the Osphena savings card — and why did mine get rejected?

The commercial savings card is for eligible commercially insured patients and excludes Medicare, Medicaid, TRICARE, and other government healthcare programs. It does not require activation, can be used at participating retail pharmacies, and the manufacturer says mail-order use is available. A rejection can come from eligibility, pharmacy participation, plan design, or processing information — and the manufacturer's own current surfaces do not agree on every GoodRx cash-processing number.

The current processing mismatch

We checked the live page and the January 2026 PDF on August 26, 2026.

For the commercial copay card, both current surfaces agree:

BIN 637765
PCN CRX
Group 99992002

For the GoodRx cash offer, they do not:

The live Osphena savings page lists BIN 610020, PCN PDM, Group 99995428.
The January 2026 PDF lists BIN 015995, PCN GDC, Group DR33.

None of this changes the drug. It can still explain a boring, maddening counter rejection.

What to do: start with the processing information on the live savings page. If the cash offer rejects, call the savings-card number and ask which current GoodRx routing set the pharmacy should use. Do not keep handing over an old screenshot and hoping the terminal changes its mind.

The deductible question — where the plan gets the final word

The manufacturer's FAQ says the patient's out-of-pocket expense can be applied to the deductible. The fuller answer is that the plan controls how manufacturer assistance is credited.

Some plans use copay-accumulator or maximizer programs that do not count manufacturer-assistance dollars toward the deductible or out-of-pocket maximum. Ask member services, by name:

“Does my plan use a copay accumulator or copay maximizer, and do Osphena savings-card dollars count toward my deductible and out-of-pocket maximum?”

That one question can matter more than the $35 headline.

If the pharmacy will not process the card

The manufacturer's FAQ says a patient can ask about a rebate check after purchase by calling the number on the back of the card. The January 2026 terms also provide a 30-day right to cancel card registration.

Save the receipt, the rejection message, and the processing numbers used. “It didn't work” is harder to fix than “BIN 637765/PCN CRX rejected with code ___ at this pharmacy.”

The hard part

Duchesnay USA says it does not currently offer a patient-assistance program.

We wish that were not true. If you are uninsured and cannot manage $190 for 90 tablets, there is no separate manufacturer free-drug program waiting behind that number. The realistic next conversations are the lower-cost treatment options above, a state pharmaceutical-assistance program, or the preferred alternatives on your plan.

That is a real dead end, and we would rather tell you here than let you discover it after a phone call.

What if my Osphena prescription was denied?

A denial names its own reason, and each reason has a different fix. Missing prior authorization needs the plan's PA form. Step-therapy denial needs the required history or a legitimate exception. Nonformulary exclusion needs the plan's coverage-review or exception process. A benefit exclusion requires the exact exclusion language and the diagnosis reviewed. High cost without a denial is a tier or deductible problem.

First, get three things out of the denial

The exact reason, word for word — not a representative's summary.
The criteria or formulary document used — ask for the title, number, and date.
The appeal or review deadline — use the date in your notice and plan documents.

Then match the reason to the fix

This table converts the wording on a claim or denial into the correct next request. The distinction matters: a missing prior authorization, unmet step therapy, nonformulary exclusion, quantity limit, benefit exclusion, and high price are six different problems. Read the exact reason first, then use the matching row instead of filing a generic appeal.

The denial or claim says	What it usually means	What to request
“Prior authorization required”	The plan has not received or completed the clinical review	The exact PA form and criteria for your plan
“Step therapy not met”	The record does not show the required product, duration, claim, or exception	Documentation of the real trial, or the policy's contraindication/intolerance/inability route
“Not on formulary” / “excluded”	Osphena is not on the member's list	The plan's nonformulary exception, coverage review, or alternative-drug process
“Quantity exceeds limit”	The claim quantity or days' supply exceeds the plan rule	Covered quantity details; prescriber review if the prescription is being processed incorrectly
“Benefit exclusion”	A drug or category is excluded, sometimes based on the indication	The exact exclusion language, diagnosis reviewed, and available appeal rights
Covered, but the price is high	Tier, deductible, coinsurance, pharmacy network, or quantity — not necessarily a denial	Test claim at preferred retail and mail-order pharmacies; ask whether tiering review exists

Who can start the review?

For Medicare Part D, you, an authorized representative, or the prescriber can request a coverage determination. A formulary exception needs a prescriber's supporting statement.

For commercial and employer plans, the denial letter and Summary Plan Description control the time limits and review route. Do not use a generic internet deadline when your notice gives a real one.

For the full appeal ladder, see our HRT prior-authorization guide.

A message you can send your prescriber's office

“My plan denied Osphena for this exact reason: [paste wording]. The plan's document says it requires: [paste criterion]. Could the office confirm that the submitted diagnosis, dose, quantity, prior-treatment history, and any applicable exception are documented accurately, and let me know whether you can submit the PA, coverage review, or appeal through [portal/fax] before [deadline]?”

Short, specific, and it gives the office something to act on instead of a feeling.

If the real problem is that you cannot get a prescriber to handle the paperwork

That is a different problem from a coverage problem, and it has a different fix.

Midi Health says it is in-network with most PPO plans nationwide, while coverage, deductibles, copays, and coinsurance remain plan-specific. That matters here because Midi bills eligible commercial insurance for visits — a model that actually matches an insurance-administration problem.

Being straight with you about the limits: Midi says it does not participate with Medicaid or Medi-Cal and cannot treat those members even as self-pay patients. It is not covered by Medicare; Medicare beneficiaries may use Midi only as self-pay patients and cannot submit Midi-related claims to Medicare. Midi is not the right door for those programs.

If you have eligible commercial coverage and the missing piece is a menopause clinician who can evaluate you and, when appropriate, manage the authorization, this is where the route starts to make sense. A visit never guarantees Osphena; prescribing remains a clinical decision.

Check whether Midi takes your plan → (Sponsored link — we may earn a commission. See our affiliate disclosure.)

Is there a generic for Osphena?

FDA approved Hetero Labs' generic ospemifene 60 mg application, ANDA 215574, on February 13, 2024 and assigned an AB therapeutic-equivalence code. Approval is not the same as current retail availability. FDA's later Orange Book records place the Hetero product in the discontinued section, so do not assume a pharmacy can order an active generic or that your plan has a generic tier for it.

We got this wrong in the first draft and caught it before publication.

Pages that say “FDA has never approved a generic Osphena” are wrong. The FDA Orange Book February 2024 changes list records the Hetero Labs 60 mg ospemifene tablet, ANDA 215574, approved February 13, 2024 with an AB code.

But it would be equally wrong to tell you that a retail generic is sitting on the shelf. The FDA's April 2025 Orange Book changes show the Hetero application in the discontinued section, which the Orange Book defines as not being marketed.

Keep the facts separate:

FDA-approved generic application? Yes.
AB-rated to the reference product? Yes.
Currently marketed and orderable? Do not assume it.
Covered differently by your plan? A separate question.

What to ask the pharmacy:

“Can you check whether any active ospemifene 60 mg NDC is currently orderable through your wholesaler, and whether my plan would cover it differently from brand Osphena?”

The answer may be no. It is still the accurate question.

Does my state have a law that can change Osphena coverage?

Three enacted state laws are directly worth checking for an Osphena dispute: Illinois requires certain state-regulated plans to cover medically necessary hormonal and non-hormonal menopause therapy; New Jersey's 2026 law applies to the State and School Employees' Health Benefits Programs; Louisiana requires menopause-care coverage but writes its prior-authorization and step-therapy ban around hormone replacement therapy, which does not clearly include Osphena.

State law is where one loose word can change the entire answer.

State law	What the enacted text does	What it means for Osphena
Illinois Public Act 103-0703, effective January 1, 2026	Requires specified state-regulated coverage for medically necessary hormonal and non-hormonal therapy to treat menopause	Worth invoking. Osphena is a non-hormonal prescription treatment for FDA-approved menopausal symptoms. The plan still decides medical necessity under the applicable contract and law.
New Jersey P.L. 2025, c. 200, effective April 9, 2026	Requires the State Health Benefits Program and School Employees' Health Benefits Program to cover medically necessary treatment for women diagnosed with perimenopause or menopause	Potentially relevant only if you are in SHBP or SEHBP. The original draft overstated this as a mandate for every New Jersey health plan.
Louisiana R.S. 22:988	Requires coverage of medically necessary menopause and perimenopause care; bars PA and step therapy for medication prescribed for hormone replacement therapy	The coverage provision may help, but the PA/ST ban is not a clean Osphena answer. Osphena is an estrogen agonist/antagonist, not hormone replacement therapy, and the statutory text does not resolve that edge case.

Two limits matter:

Many self-funded employer plans are governed by ERISA and can sit outside state insurance mandates. Ask HR or the plan administrator whether the plan is self-funded.
A state mandate does not turn a manufacturer commercial savings card into a government-program benefit. Coverage law and coupon eligibility are separate.

If a state law appears to apply and the plan says no, request the answer in writing and contact the state insurance department or program administrator named by the law. Do not argue from a headline. Send the enacted section.

Can I use HSA or FSA money for Osphena?

A prescription medication used for a medical condition generally falls within qualified medical expenses for an HSA or health FSA. Osphena is therefore typically eligible when you pay an unreimbursed amount, but your account's substantiation rules still apply. You cannot reimburse the same expense twice or treat an insurance-reimbursed amount as your own qualified out-of-pocket cost.

Keep five things:

the prescription record;
an itemized pharmacy receipt showing the drug, date, quantity, and amount paid;
the explanation of benefits if insurance was billed;
any savings-program record that changed the final amount;
the HSA/FSA reimbursement record.

The current authorities are IRS Publication 969 and Publication 502, plus your own plan administrator.

HSA/FSA eligibility does not make Osphena covered by insurance. It changes the tax treatment of eligible out-of-pocket spending. That is a different door.

Before you fight for coverage, is Osphena the right thing to fight for?

Osphena is an FDA-approved prescription drug — not a controlled substance — and the label requires one 60 mg tablet daily with food. It is an estrogen agonist/antagonist with tissue-selective effects, not menopausal hormone therapy. It still carries a boxed warning for endometrial cancer and cardiovascular disorders. The insurance paperwork never replaces a clinician's review of those risks, contraindications, interactions, and your symptoms.

A page that only teaches you to win an insurance argument has done half its job.

Osphena is not hormone replacement therapy — and “non-hormonal” does not mean no risk

The FDA prescribing information describes Osphena as an estrogen agonist/antagonist with tissue-selective effects. In the endometrium, it has estrogen-agonist effects. That is why the boxed warning includes endometrial cancer.

In February 2026, FDA approved boxed-warning changes for six menopausal hormone-therapy products. Those class-specific changes did not alter Osphena's label, because Osphena is not an MHT product.

Who the label says should not use it

The current label lists these contraindications:

undiagnosed abnormal genital bleeding;
known or suspected estrogen-dependent neoplasia;
active or past deep-vein thrombosis or pulmonary embolism;
active or past arterial thromboembolic disease, including stroke or myocardial infarction;
hypersensitivity to Osphena or its ingredients;
known or suspected pregnancy.

The label says Osphena is not recommended for women with severe hepatic impairment and describes important drug-interaction concerns. Some payer forms repeat those safety checks because the insurer is asking the prescriber to document label-consistent use.

How long before it may help?

The manufacturer says most women in its clinical studies reported relief in as little as 12 weeks. The pivotal label data also use 12-week endpoints. That is not a guarantee for an individual woman, and it is worth noticing when a plan grants only a three-month initial authorization.

When to stop reading an insurance page and get care

Any postmenopausal bleeding needs prompt clinical evaluation. New or unexplained bleeding while taking Osphena should be reported promptly. Chest pain, sudden shortness of breath, sudden vision or speech changes, sudden weakness, a severe new headache, or severe leg pain can require emergency care. Call 911 for emergency symptoms.

This page is not a screening tool and cannot tell you whether Osphena is appropriate.

What do other women say about paying for Osphena?

Coverage is not a side issue in public Osphena reviews; it is often the deciding issue. WebMD's current Osphena review page shows a 3.3 out of 5 average from 225 ratings, and its most-voted positive review ends with the complaint, “But Medicare won't cover it!” That is one member's plan outcome, not a Medicare-wide rule — which is exactly why plan-specific verification matters.

We did not build a testimonial wall. We used one short, attributable line because it captures the trigger behind this search.

Treat public reviews for what they are: individual experience, not proof of typical efficacy, safety, or coverage. We have no relationship with the reviewers, and we did not use any review to support a medical claim.

The useful pattern is not the star rating. It is the collision between a drug someone wants to continue and a benefit that changes at the counter.

How did The HRT Index verify this page?

We verified the FDA label, generic approval and marketing record, 12 named plan documents, the live manufacturer savings page, the January 2026 savings card, current Part D cost rules, three state laws, and the provider terms behind the two sponsored routes. We separated what a payer or manufacturer states from what an independent primary source confirms, and we refused to publish a national coverage percentage we could not substantiate.

Provider- or payer-stated versus independently verified

This table separates what the payer, manufacturer, or provider says from what The HRT Index independently checked. It records the source-specific claim, the verification step, and the date. That matters because a published policy can be real without being your policy, and a manufacturer price can be current without being the price your claim returns.

Claim	What the organization states	What we independently checked	Verification date
UHC diagnosis split	UHC's policy separates benefit designs that cover versus exclude sexual-dysfunction drugs	Effective date, diagnoses, 12-month duration, and member-benefit caveat in the policy PDF	August 2026
Centene prerequisite sequence	Two lubricants/moisturizers plus at least four weeks of one vaginal estrogen, with exceptions	Current CP.PMN.168 text and November 2025 review date; removed the draft's false “maximum labeled doses” wording for OTC products	August 2026
Rhode Island paid-claim logic	A prior formulary vaginal-estrogen claim can satisfy step logic	Policy reviewed March 2026 checks the prior 365 days	August 2026
Medicare dyspareunia rule	Part D plans still set formularies and utilization rules	CMS's 2018 clarification says FDA-labeled menopausal dyspareunia treatment is not automatically excluded	August 2026
Manufacturer price ladder	$35/30 or $90/90 commercial mail order; $45/30 retail; $190/90 cash; $85/30 or $205/90 GoodRx route	Live page and January 2026 card checked against each other	August 26, 2026
Generic status	Hetero's ospemifene ANDA was FDA-approved	FDA Orange Book records show the AB-rated approval and later discontinued/not-marketed placement	August 2026
Midi insurance limits	In-network with most PPO plans; no Medicaid participation; Medicare self-pay only	Current Midi insurance page	August 2026
Sesame cash-pay limits	No third-party insurance; prescriptions are never guaranteed	Current Sesame terms also require users to certify they are not federal-program beneficiaries	August 2026

What we refused to publish

a national coverage rate;
a denial-rate statistic;
“most plans cover it”;
a claim that Medicare cannot cover menopausal dyspareunia;
a retail generic price when the FDA-listed generic is not currently marketed;
a cash price whose quantity was not visible;
a fake medical reviewer, testimonial, firsthand treatment story, or numeric provider score.

What we corrected before publication

Our first draft said no generic ospemifene had been FDA-approved. That was wrong. FDA approved ANDA 215574 on February 13, 2024, and later Orange Book records place it in the discontinued section.

The first draft also said Medicare Part D was legally barred from covering Osphena for dyspareunia unless vaginal dryness was the diagnosis. That was wrong. CMS clarified in 2018 that FDA-labeled treatment of menopausal dyspareunia is not automatically excluded.

And the first draft described Centene as requiring two OTC products at “maximum labeled doses.” The current policy does not say that. It requires two lubricants or moisturizers plus a separate four-week vaginal-estrogen trial, with written exceptions.

We are disclosing those corrections under our corrections policy, because a page about reading documents carefully should be honest about what changed.

This page was produced under The HRT Index Verification Standard. We read every published price, separate FDA-approved from compounded options, verify state availability and insurance, and re-check on a fixed schedule. This is editorial research and is not medically reviewed by a clinician. See our editorial standards and medical review policy.

When this page goes stale: manufacturer prices and processing details are re-checked monthly. Formularies and payer criteria are re-checked quarterly and at January and July plan-year changes. FDA label and generic status are re-checked quarterly. State laws are re-checked when an effective date or amendment lands. The visible “Last verified” date changes only when the checks are actually performed.

Where can I get an Osphena prescription if I am paying cash?

A cash price does not solve the prescription problem. Osphena still requires a licensed clinician to decide whether it is appropriate and issue a prescription. If you already have a prescriber, use the manufacturer route directly. If you need a self-pay evaluation, compare the visit price before booking and understand that no legitimate platform can promise Osphena in advance.

Some women have already done the math and decided that about $63 per month through the 90-day manufacturer cash route is worth avoiding weeks of authorization work. Fair enough.

Sesame Care is a self-pay marketplace where available clinicians list visit prices before booking. Sesame says it does not accept Medicare, Medicaid, or other third-party insurance, and its terms require users to certify they are not beneficiaries of Medicare, Medicaid, TRICARE, or another federal healthcare program. It also states that medication is prescribed only at the clinician's discretion and only when medically necessary.

That means Sesame is not a workaround for federal-program rules, and paying for a visit is not buying a prescription. It is simply a transparent self-pay evaluation route for someone who fits the terms.

See the current price of a self-pay menopause visit → (Sponsored provider link — we may earn a commission. See our affiliate disclosure.)

Frequently asked questions

These short answers close the questions that most often follow an Osphena coverage check: Medicare and Medicaid eligibility, current insured and cash prices, prior authorization, savings-card restrictions, generic status, tax-advantaged accounts, drug class, controlled-substance status, and lower-cost alternatives. Each answer points back to the fuller evidence above.

Does insurance cover Osphena?

Some commercial, Medicare Part D, and Medicaid plans cover Osphena, but restrictions vary. The 12 documents reviewed for this page show preferred coverage, prior authorization, diagnosis-sensitive coverage, step therapy, Tier 3 quantity limits, and formulary exclusion. Your member-specific formulary and live claim decide your answer.

Does Medicare Part D cover Osphena?

It can cover Osphena for either FDA-approved indication. CMS clarified that FDA-labeled treatment of moderate-to-severe dyspareunia due to menopause is not automatically excluded as sexual-dysfunction treatment. The plan can still apply its formulary, prior authorization, quantity limit, pharmacy network, and cost-sharing rules.

Does Medicaid cover Osphena?

It depends on the state and managed-care plan. Iowa's posted form denies dyspareunia requests and considers vaginal dryness after a preferred vaginal-estrogen trial. Other Medicaid plans use different criteria, so search the state's current preferred-drug list and Osphena PA form by name.

How much does Osphena cost with insurance?

There is no universal insured copay. The manufacturer publishes $35 for 30 tablets or $90 for 90 through Osphena At Home for eligible commercial-insurance patients, and $45 for 30 tablets through its retail commercial card. Your tier, deductible, pharmacy, accumulator rules, and quantity can change the real amount.

How much is Osphena without insurance?

The manufacturer publishes $190 for 90 tablets through Osphena At Home, about $63.33 per month. Its funded GoodRx route lists $85 for 30 tablets or $205 for 90. Program terms and prices can change, so verify them on the live savings page before the prescription is sent.

Does Osphena require prior authorization?

Many plans require it, but not every plan. UnitedHealthcare, CVS Caremark, Iowa Medicaid, and the Mass General Brigham Part D document reviewed here use prior authorization. UMWA lists Osphena as preferred, while Cigna's two public lists show Tier 3 with a quantity limit.

Why was my Osphena prescription denied?

Common reasons are missing prior authorization, unmet step therapy, a quantity limit, nonformulary status, a category exclusion, or a diagnosis-specific rule. Read the exact denial. Each reason needs a different response.

Can I use the Osphena savings card with Medicare?

No. The commercial savings offers exclude people enrolled in Medicare, Medicaid, TRICARE, or another government healthcare program. A Part D member may choose the separate cash route outside the benefit, but the manufacturer terms say that payment cannot be reimbursed by Part D and does not count toward the Part D out-of-pocket threshold.

Is there a generic for Osphena?

FDA approved Hetero Labs' ospemifene 60 mg ANDA on February 13, 2024 and assigned an AB code. Later Orange Book records place that product in the discontinued section, so a currently marketed retail generic should not be assumed. Ask the pharmacy whether any active ospemifene NDC is orderable.

Is Osphena HSA or FSA eligible?

A prescribed medication used for a medical condition generally qualifies as a medical expense for an HSA or health FSA when you pay an unreimbursed amount. Keep the itemized receipt and confirm your account's substantiation rules.

Is Osphena a hormone?

Osphena is not hormone replacement therapy. The FDA label describes it as an estrogen agonist/antagonist with tissue-selective effects. It acts like estrogen in some tissues, including the endometrium, and carries a boxed warning for endometrial cancer and cardiovascular disorders.

Is Osphena a controlled substance?

No. The current DailyMed label lists no DEA schedule. Osphena is still a prescription drug and must be prescribed by a licensed clinician.

What is a cheaper alternative to Osphena?

Plan documents most often name generic estradiol vaginal cream, estradiol vaginal tablets or inserts, and Premarin Vaginal Cream. A GoodRx snapshot checked August 26, 2026 listed one 42.5-gram tube of generic estradiol 0.01% cream at $35.09. Whether a local vaginal product fits you is a clinical decision.

Still not sure which HRT program is right for you?

If you still do not know whether Osphena, local treatment, or a broader menopause-care route fits your situation, do not force the insurance question to make the clinical decision. Use the matching tool below for a personalized starting route and a clear flag when online care is not the right first step.

If this page left you thinking, Okay, but is Osphena even the right route for me? — that is a good instinct, and it is a different question from insurance coverage.

Use our free, private, about-90-second matching tool. It asks about your symptoms, route preference, insurance situation, safety history, and state, then shows a best-fit starting route and two backups — including when online care is not the right first step.

Find My HRT Path →

Educational content only. Not medical advice, legal advice, tax advice, or a benefit verification. Only your plan can determine your coverage, and only a licensed clinician can determine whether a medication is appropriate for you.

Which sources were checked?

The source set is weighted toward primary documents: FDA labeling and Orange Book records, CMS and Medicare materials, statutes, payer criteria, formularies, manufacturer terms, and provider policies. GoodRx is used only for a dated cash-price snapshot, and WebMD is used only for attributed consumer voice — never as medical or coverage evidence.

Keep the Osphena coverage question in context

See the current Osphena cash-price routes, compare Osphena with Intrarosa, read the Osphena prescription guide, or review the broader HRT insurance guide before deciding what to do next.

Keep reading: